Trade Bionano Genomics, Inc. - BNGO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.0300 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Bionano Genomics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.05 |
Open* | 1.08 |
1-Year Change* | -1.68% |
Day's Range* | 1.08 - 1.15 |
52 wk Range | 1.18-20.20 |
Average Volume (10 days) | 1.91M |
Average Volume (3 months) | 34.12M |
Market Cap | 47.39M |
P/E Ratio | -100.00K |
Shares Outstanding | 38.84M |
Revenue | 33.61M |
EPS | -6.98 |
Dividend (Yield %) | N/A |
Beta | 2.41 |
Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 1.0500 | 0.0200 | 1.94% | 1.0300 | 1.1200 | 1.0300 |
Mar 26, 2024 | 1.0200 | -0.0100 | -0.97% | 1.0300 | 1.0400 | 1.0100 |
Mar 25, 2024 | 1.0100 | -0.0300 | -2.88% | 1.0400 | 1.0900 | 1.0100 |
Mar 22, 2024 | 1.0200 | -0.0100 | -0.97% | 1.0300 | 1.0400 | 1.0100 |
Mar 21, 2024 | 1.0400 | -0.0100 | -0.95% | 1.0500 | 1.0800 | 1.0400 |
Mar 20, 2024 | 1.0300 | 0.0100 | 0.98% | 1.0200 | 1.0400 | 0.9900 |
Mar 19, 2024 | 1.0200 | 0.0100 | 0.99% | 1.0100 | 1.0500 | 1.0000 |
Mar 18, 2024 | 1.0100 | 0.0100 | 1.00% | 1.0000 | 1.0100 | 0.9860 |
Mar 15, 2024 | 1.0000 | -0.0100 | -0.99% | 1.0100 | 1.0500 | 1.0000 |
Mar 14, 2024 | 1.0000 | -0.0700 | -6.54% | 1.0700 | 1.0700 | 0.9900 |
Mar 13, 2024 | 1.0600 | 0.0100 | 0.95% | 1.0500 | 1.0900 | 1.0500 |
Mar 12, 2024 | 1.0500 | -0.0400 | -3.67% | 1.0900 | 1.0900 | 1.0500 |
Mar 11, 2024 | 1.0900 | -0.0400 | -3.54% | 1.1300 | 1.1700 | 1.0900 |
Mar 8, 2024 | 1.1200 | -0.0200 | -1.75% | 1.1400 | 1.2400 | 1.1000 |
Mar 7, 2024 | 1.1300 | -0.0300 | -2.59% | 1.1600 | 1.2100 | 1.1300 |
Mar 6, 2024 | 1.1800 | 0.0400 | 3.51% | 1.1400 | 1.2200 | 1.0500 |
Mar 5, 2024 | 1.1800 | 0.0100 | 0.85% | 1.1700 | 1.2200 | 1.1500 |
Mar 4, 2024 | 1.2100 | -0.0600 | -4.72% | 1.2700 | 1.2753 | 1.1600 |
Mar 1, 2024 | 1.2500 | -0.0100 | -0.79% | 1.2600 | 1.2700 | 1.2300 |
Feb 29, 2024 | 1.2500 | -0.0600 | -4.58% | 1.3100 | 1.3403 | 1.2320 |
Bionano Genomics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, May 7, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Bionano Genomics Inc Earnings Release Q1 2024 Bionano Genomics Inc Earnings ReleaseForecast -Previous - |
Thursday, June 13, 2024 | ||
Time (UTC) 17:00 | Country US
| Event Bionano Genomics Inc Annual Shareholders Meeting Bionano Genomics Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 27.802 | 17.981 | 8.503 | 10.1295 | 12.0007 |
Revenue | 27.802 | 17.981 | 8.503 | 10.1295 | 12.0007 |
Cost of Revenue, Total | 21.857 | 14.107 | 5.73 | 6.76815 | 8.71133 |
Gross Profit | 5.945 | 3.874 | 2.773 | 3.36136 | 3.28941 |
Total Operating Expense | 159.5 | 95.383 | 47.054 | 37.3379 | 32.4158 |
Selling/General/Admin. Expenses, Total | 80.996 | 55.59 | 29.468 | 20.1554 | 14.2203 |
Research & Development | 49.047 | 22.485 | 10.256 | 9.08089 | 9.48416 |
Unusual Expense (Income) | 1.8 | 1.801 | 1.5 | 1.3335 | 0 |
Operating Income | -131.698 | -77.402 | -38.551 | -27.2084 | -20.4151 |
Interest Income (Expense), Net Non-Operating | 1.209 | -0.691 | -2.519 | -2.2862 | -1.38102 |
Other, Net | -0.223 | -0.059 | -0.007 | -0.29942 | 3.31523 |
Net Income Before Taxes | -130.712 | -78.152 | -41.077 | -29.794 | -18.4809 |
Net Income After Taxes | -132.596 | -72.435 | -41.106 | -29.8151 | -18.4964 |
Net Income Before Extra. Items | -132.596 | -72.435 | -41.106 | -29.8151 | -18.4964 |
Net Income | -132.596 | -72.435 | -41.106 | -29.8151 | -18.4964 |
Income Available to Common Excl. Extra. Items | -132.596 | -72.435 | -41.106 | -29.8151 | -18.4964 |
Income Available to Common Incl. Extra. Items | -132.596 | -72.435 | -41.106 | -29.8151 | -18.4964 |
Diluted Net Income | -132.596 | -72.435 | -41.106 | -29.8151 | -18.4964 |
Diluted Weighted Average Shares | 28.921 | 27.6782 | 10.4251 | 1.49779 | 1.00551 |
Diluted EPS Excluding Extraordinary Items | -4.58477 | -2.61704 | -3.94298 | -19.906 | -18.3951 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -4.54431 | -2.57475 | -3.84946 | -19.3273 | -18.3951 |
Total Extraordinary Items | 0 | ||||
Depreciation / Amortization | 5.8 | 1.4 | 0.1 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 8.662 | 7.415 | 8.215 | 7.221 | 6.67 |
Revenue | 8.662 | 7.415 | 8.215 | 7.221 | 6.67 |
Cost of Revenue, Total | 6.354 | 5.345 | 6.41 | 5.412 | 5.199 |
Gross Profit | 2.308 | 2.07 | 1.805 | 1.809 | 1.471 |
Total Operating Expense | 47.9 | 45.258 | 45.742 | 39.37 | 38.749 |
Selling/General/Admin. Expenses, Total | 26.936 | 25.976 | 23.521 | 21.216 | 21.783 |
Research & Development | 14.61 | 13.937 | 14.011 | 12.742 | 11.767 |
Unusual Expense (Income) | 1.8 | 0 | 0 | ||
Operating Income | -39.238 | -37.843 | -37.527 | -32.149 | -32.079 |
Interest Income (Expense), Net Non-Operating | 0.615 | 0.628 | 0.695 | 0.363 | 0.118 |
Other, Net | -0.256 | 0.117 | -0.04 | 0.005 | -0.156 |
Net Income Before Taxes | -38.879 | -37.098 | -36.872 | -31.781 | -32.117 |
Net Income After Taxes | -38.912 | -37.124 | -38.677 | -31.809 | -32.158 |
Net Income Before Extra. Items | -38.912 | -37.124 | -38.677 | -31.809 | -32.158 |
Net Income | -38.912 | -37.124 | -38.677 | -31.809 | -32.158 |
Income Available to Common Excl. Extra. Items | -38.912 | -37.124 | -38.677 | -31.809 | -32.158 |
Income Available to Common Incl. Extra. Items | -38.912 | -37.124 | -38.677 | -31.809 | -32.158 |
Diluted Net Income | -38.912 | -37.124 | -38.677 | -31.809 | -32.158 |
Diluted Weighted Average Shares | 31.498 | 30.2045 | 29.6953 | 28.9701 | 28.5554 |
Diluted EPS Excluding Extraordinary Items | -1.23538 | -1.22909 | -1.30246 | -1.09799 | -1.12616 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.23538 | -1.22909 | -1.26306 | -1.09799 | -1.12616 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 157.298 | 272.414 | 46.789 | 28.2582 | 23.0251 |
Cash and Short Term Investments | 113.186 | 250.612 | 38.449 | 17.3114 | 16.5227 |
Cash & Equivalents | 5.091 | 24.571 | 38.449 | 17.3114 | 16.5227 |
Total Receivables, Net | 7.496 | 5.321 | 2.775 | 6.33396 | 4.51433 |
Accounts Receivable - Trade, Net | 7.022 | 4.934 | 2.775 | 6.33396 | 4.51433 |
Total Inventory | 29.761 | 12.387 | 3.315 | 3.44356 | 1.06856 |
Prepaid Expenses | 4.443 | 1.746 | 1.788 | 0.71228 | 0.53537 |
Other Current Assets, Total | 2.412 | 2.348 | 0.462 | 0.45706 | 0.38413 |
Total Assets | 307.502 | 377.1 | 60.45 | 30.2079 | 24.8024 |
Property/Plant/Equipment, Total - Net | 28.958 | 20.935 | 4.91 | 1.94963 | 1.7773 |
Property/Plant/Equipment, Total - Gross | 42.035 | 30.007 | 12.366 | 8.22309 | 6.93967 |
Accumulated Depreciation, Total | -13.077 | -9.072 | -7.456 | -6.27347 | -5.16236 |
Total Current Liabilities | 35.884 | 21.84 | 8.945 | 26.367 | 4.52286 |
Accounts Payable | 12.534 | 9.696 | 2.93 | 2.69915 | 1.35174 |
Accrued Expenses | 11.97 | 10.484 | 5.037 | 2.9573 | 2.90013 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.285 | 0.299 | 0 | 20.0849 | 0 |
Other Current Liabilities, Total | 11.095 | 1.361 | 0.978 | 0.62562 | 0.271 |
Total Liabilities | 58.104 | 39.982 | 25.368 | 26.5942 | 14.6651 |
Total Long Term Debt | 3.619 | 3.642 | 16.325 | 0 | 9.02937 |
Long Term Debt | 0 | 16.325 | 0 | 9.02937 | |
Other Liabilities, Total | 18.601 | 14.5 | 0.098 | 0.22713 | 1.11283 |
Total Equity | 249.398 | 337.118 | 35.082 | 3.61372 | 10.1374 |
Redeemable Preferred Stock | 0 | ||||
Common Stock | 0.03 | 0.029 | 0.019 | 0.00343 | 0.001 |
Additional Paid-In Capital | 599.207 | 553.747 | 178.747 | 106.188 | 82.8988 |
Retained Earnings (Accumulated Deficit) | -348.715 | -216.119 | -143.684 | -102.577 | -72.7624 |
Total Liabilities & Shareholders’ Equity | 307.502 | 377.1 | 60.45 | 30.2079 | 24.8024 |
Total Common Shares Outstanding | 29.7183 | 28.9602 | 18.9953 | 3.42745 | 1.00551 |
Goodwill, Net | 77.289 | 56.16 | 7.173 | 0 | |
Intangibles, Net | 41.143 | 26.842 | 1.475 | 0 | |
Other Long Term Assets, Total | 2.814 | 0.749 | 0.103 | 0 | |
Short Term Investments | 108.095 | 226.041 | 0 | ||
Capital Lease Obligations | 3.619 | 3.642 | 0 | ||
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Other Equity, Total | -1.124 | -0.539 | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 104.537 | 122.575 | 142.557 | 157.298 | 218.197 |
Cash and Short Term Investments | 63.582 | 77.062 | 95.808 | 113.186 | 180.19 |
Cash & Equivalents | 34.568 | 14.856 | 4.104 | 5.091 | 28.166 |
Total Receivables, Net | 8.669 | 7.613 | 6.78 | 7.496 | 5.829 |
Accounts Receivable - Trade, Net | 8.669 | 7.613 | 6.78 | 7.022 | 5.829 |
Total Inventory | 26.429 | 32.453 | 33.113 | 29.761 | 25.046 |
Prepaid Expenses | 5.857 | 5.447 | 6.856 | 4.443 | 7.132 |
Total Assets | 181.904 | 271.381 | 292.151 | 307.502 | 323.698 |
Property/Plant/Equipment, Total - Net | 30.991 | 30.566 | 29.769 | 28.958 | 25.648 |
Goodwill, Net | 0 | 77.281 | 77.289 | 77.289 | 56.466 |
Intangibles, Net | 35.766 | 37.559 | 39.351 | 41.143 | 22.585 |
Other Long Term Assets, Total | 10.61 | 3.4 | 3.185 | 2.814 | 0.802 |
Total Current Liabilities | 40.194 | 33.499 | 38.135 | 35.884 | 33.5 |
Accounts Payable | 15.369 | 11.912 | 15.78 | 12.534 | 9.407 |
Accrued Expenses | 12.997 | 9.416 | 10.62 | 11.97 | 12.757 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 11.552 | 11.892 | 11.453 | 11.095 | 11.048 |
Total Liabilities | 62.905 | 56.625 | 60.664 | 58.104 | 41.956 |
Total Long Term Debt | 3.595 | 3.604 | 3.612 | 3.619 | 3.626 |
Long Term Debt | |||||
Other Liabilities, Total | 19.116 | 19.522 | 18.917 | 18.601 | 4.83 |
Total Equity | 118.999 | 214.756 | 231.487 | 249.398 | 281.742 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.003 | 0.003 | 0.031 | 0.03 | 0.03 |
Additional Paid-In Capital | 656.406 | 639.814 | 617.96 | 599.207 | 593.572 |
Retained Earnings (Accumulated Deficit) | -537.317 | -424.751 | -385.839 | -348.715 | -310.038 |
Total Liabilities & Shareholders’ Equity | 181.904 | 271.381 | 292.151 | 307.502 | 323.698 |
Total Common Shares Outstanding | 35.349 | 33.24 | 30.679 | 29.7183 | 29.69 |
Short Term Investments | 29.014 | 62.206 | 91.704 | 108.095 | 152.024 |
Other Equity, Total | -0.093 | -0.31 | -0.665 | -1.124 | -1.822 |
Other Current Assets, Total | 2.412 | ||||
Property/Plant/Equipment, Total - Gross | 42.035 | ||||
Accumulated Depreciation, Total | -13.077 | ||||
Current Port. of LT Debt/Capital Leases | 0.276 | 0.279 | 0.282 | 0.285 | 0.288 |
Capital Lease Obligations | 3.595 | 3.604 | 3.612 | 3.619 | 3.626 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -132.596 | -72.435 | -41.106 | -29.8151 | -18.4964 |
Cash From Operating Activities | -124.816 | -71.927 | -38.314 | -29.5297 | -19.9438 |
Cash From Operating Activities | 9.84 | 3.37 | 1.479 | 1.12785 | 1.32052 |
Non-Cash Items | 24.768 | 10.567 | 4.753 | 4.12957 | -0.39911 |
Cash Interest Paid | 0.298 | 1.91 | 1.252 | 1.27718 | 0.70035 |
Changes in Working Capital | -28.588 | -7.652 | -3.44 | -4.97207 | -2.36887 |
Cash From Investing Activities | 82.767 | -278.062 | -2.45 | -0.06106 | -0.33172 |
Capital Expenditures | -2.408 | -0.822 | 0 | -0.06106 | -0.33172 |
Cash From Financing Activities | 23.007 | 336.111 | 61.902 | 30.3794 | 35.7764 |
Issuance (Retirement) of Stock, Net | 23.471 | 352.82 | 68.625 | 20.4173 | 19.3935 |
Issuance (Retirement) of Debt, Net | -0.036 | -15.005 | -4.723 | 9.82038 | 16.3829 |
Net Change in Cash | -19.08 | -13.878 | 21.138 | 0.78864 | 15.5008 |
Financing Cash Flow Items | -0.428 | -1.704 | -2 | 0.14171 | |
Deferred Taxes | 1.76 | -5.777 | 0 | ||
Other Investing Cash Flow Items, Total | 85.175 | -277.24 | -2.45 | ||
Foreign Exchange Effects | -0.038 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -37.124 | -132.596 | -93.919 | -62.112 | -29.952 |
Cash From Operating Activities | -32.413 | -124.816 | -90.299 | -60.826 | -32.494 |
Cash From Operating Activities | 3.241 | 9.84 | 7.023 | 4.592 | 2.239 |
Non-Cash Items | 4.797 | 24.768 | 18.49 | 12.128 | 5.779 |
Cash Interest Paid | 0.076 | 0.298 | 0.222 | 0.139 | 0.07 |
Changes in Working Capital | -3.327 | -28.588 | -21.893 | -15.434 | -10.56 |
Cash From Investing Activities | 16.528 | 82.767 | 71.157 | 63.204 | 31.964 |
Capital Expenditures | -0.36 | -2.408 | -1.741 | -1.451 | -0.982 |
Cash From Financing Activities | 14.862 | 23.007 | 22.861 | 0.21 | 0.007 |
Financing Cash Flow Items | -0.38 | -0.428 | -0.503 | 0.075 | 0 |
Issuance (Retirement) of Stock, Net | 15.252 | 23.471 | 23.39 | 0.152 | 0.015 |
Issuance (Retirement) of Debt, Net | -0.01 | -0.036 | -0.026 | -0.017 | -0.008 |
Net Change in Cash | -0.987 | -19.08 | 3.595 | 2.588 | -0.523 |
Other Investing Cash Flow Items, Total | 16.888 | 85.175 | 72.898 | 64.655 | 32.946 |
Deferred Taxes | 1.76 | ||||
Foreign Exchange Effects | 0.036 | -0.038 | -0.124 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Bionano Genomics, Inc. Company profile
Bionano Genomics (BNGO) is a provider of solutions for genome analysis. Additionally, the company offers diagnostic services, software and optical genome mapping solutions for basic, translational and clinical research applications.
Based in San Diego, California, the company has two businesses: Lineagen and BioDiscovery.
Lineagen provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental impairments.
Through BioDiscovery, the company also offers an industry-leading, platform-diagnostic software solution. Integrating next-generation sequencing and microarray data to analyse, visualise, interpret, and report copy number variants, single-nucleotide variants, and the absence of heterozygosity across the genome in a single consolidated view.
In October 2021, Bionano Genomics bought Biodiscovery, a software company that provides solutions for analysing, interpreting and reporting genomics data.
The acquisition is expected to accelerate the adoption of optical genome mapping (OGM), with the integration of BioDiscovery's NxClinical software solution. Saphyr System is Bionano’s featured product for OGM.
Saphyr is an ultra-sensitive genome analysis platform that can detect structural variations for mosaic samples or heterogeneous cancer samples with a false positive rate of less than 2%.
The company, founded in 2003, sells its products for research use in laboratories associated with academic and governmental research institutions. For North America and Europe, Bionano sells its products through a direct sales force. It also sells its products via third party distributors in China, Japan, South Korea, Singapore, Australia, India and South Africa.
Bionano became a public company in September 2018. Its shares are traded on the Nasdaq under the ticker symbol BNGO.
Industry: | Advanced Medical Equipment & Technology (NEC) |
9640 Towne Centre Drive
9640 Towne Centre Drive
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com